ESMO 2024 | Impact of weight loss intervention on physical activity in the BeWEL trial

Jennifer Ligibel • 16 Sep 2024

ESMO 2024

Breast Cancer

BeWEL

Jennifer Ligibel, MD, Dana Farber Cancer Institute, Boston, MA, discusses a pre-planned secondary analysis from the BeWEL trial (NCT02750826), which evaluates the effects of a weight loss intervention (WLI) on moderate/vigorous physical activity (MVPA) in patients with breast cancer with a BMI ≥27 kg/m². The WLI involved phone-based health coaching, promoting caloric restriction and 150 minutes of MVPA per week. Results showed a significant increase in physical activity in the WLI group at six months, with more patients achieving 150+ minutes per week compared to the control, positively correlating with greater weight loss. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.